113 related articles for article (PubMed ID: 12704457)
1. [Molecular diagnostics of malignant melanoma: molecular staging, minimal residual disease].
Tímár J; Csuka O
Magy Onkol; 2003; 47(1):63-6. PubMed ID: 12704457
[TBL] [Abstract][Full Text] [Related]
2. Molecular diagnostics in melanoma.
Carlson JA; Ross JS; Slominski A; Linette G; Mysliborski J; Hill J; Mihm M
J Am Acad Dermatol; 2005 May; 52(5):743-75; quiz 775-8. PubMed ID: 15858465
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis and significance of minimal residual disease in patients with colorectal carcinoma].
von Knebel Doeberitz M; Koch M; Weitz J; Herfarth C
Zentralbl Chir; 2000; 125 Suppl 1():15-9. PubMed ID: 10929641
[TBL] [Abstract][Full Text] [Related]
4. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection.
Rutkowski P; Nowecki ZI; Kulik J; Ruka W; Siedlecki JA
Melanoma Res; 2008 Aug; 18(4):246-52. PubMed ID: 18626308
[TBL] [Abstract][Full Text] [Related]
5. Detection of disseminated melanoma cells by reverse-transcription - polymerase chain reaction.
Samija I; Lukac J; Kusić Z; Situm M; Samija M
Coll Antropol; 2007 Dec; 31(4):1187-94. PubMed ID: 18217480
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients.
Mangas C; Hilari JM; Paradelo C; Rex J; Fernández-Figueras MT; Fraile M; Alastrue A; Ferrándiz C
Ann Surg Oncol; 2006 Jul; 13(7):910-8. PubMed ID: 16788751
[TBL] [Abstract][Full Text] [Related]
8. Molecular upstaging of sentinel lymph nodes in melanoma: where are we now?
Martinez SR; Mori T; Hoon DS
Surg Oncol Clin N Am; 2006 Apr; 15(2):331-40. PubMed ID: 16632218
[TBL] [Abstract][Full Text] [Related]
9. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.
Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA
Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
11. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
12. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision.
Abrahamsen HN; Hamilton-Dutoit SJ; Larsen J; Steiniche T
Cancer; 2004 Apr; 100(8):1683-91. PubMed ID: 15073857
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
Quaglino P; Osella-Abate S; Cappello N; Ortoncelli M; Nardò T; Fierro MT; Cavallo F; Savoia P; Bernengo MG
Melanoma Res; 2007 Apr; 17(2):75-82. PubMed ID: 17496782
[TBL] [Abstract][Full Text] [Related]
14. [Current biological markers of cutaneous melanoma progression].
Stoitchkov K; Le Bricon T
Ann Biol Clin (Paris); 2000; 58(2):157-65. PubMed ID: 10760702
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
16. Methods of detection of circulating melanoma cells: a comparative overview.
Nezos A; Msaouel P; Pissimissis N; Lembessis P; Sourla A; Armakolas A; Gogas H; Stratigos AJ; Katsambas AD; Koutsilieris M
Cancer Treat Rev; 2011 Jun; 37(4):284-90. PubMed ID: 21106295
[TBL] [Abstract][Full Text] [Related]
17. Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node.
Davids V; Kidson SH; Hanekom GS
Melanoma Res; 2003 Jun; 13(3):313-24. PubMed ID: 12777989
[TBL] [Abstract][Full Text] [Related]
18. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma.
Page AJ; Carlson GW; Delman KA; Murray D; Hestley A; Cohen C
Am Surg; 2007 Jul; 73(7):674-8; discussion 678-9. PubMed ID: 17674939
[TBL] [Abstract][Full Text] [Related]
19. Microphthalmia-associated transcription factor and tyrosinase as markers of melanoma cells in blood of patients with melanoma.
Samija I; Lukac J; Marić-Brozić J; Kusić Z
Croat Med J; 2004 Apr; 45(2):142-8. PubMed ID: 15103749
[TBL] [Abstract][Full Text] [Related]
20. Molecular staging for patients with malignant melanoma.
Shivers S; Jakub J; Pendas S; Reintgen D
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1665-74. PubMed ID: 18020932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
